ArticleBMC endocrine disorders2025
Prevalence and determinants of comorbidities among patients with type 2 diabetes mellitus in Nepal: a cross-sectional study.
Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundType 2 diabetes mellitus (T2DM) is a growing global health burden often accompanied by multiple comorbidities that complicate management and worsen clinical outcomes. Understanding the epidemiological profile of these comorbid conditions is essential for developing integrated and effective diabetes care strategies, particularly in low- and middle-income countries such as Nepal. This study aimed to determine the prevalence and factors associated with common comorbidities among patients with T2DM in Nepal.
methodsThis was a cross-sectional household study. The primary data was collected from T2DM patients in Madhesh Province, Nepal. Multistage sampling was used to select 492 patients with T2DM from the population. Data was collected through structured interviews, and comorbidities were documented based on patients self-reports and subsequently verified with physician prescriptions. Data on demographic characteristics, clinical profiles, and behaviour and lifestyle factors were collected as potential predictors of comorbidities. Descriptive statistics and logistic regression were employed to determine the prevalence and associated factors of comorbidities.
resultsAmong 492 patients with T2DM, 92.1% had at least one comorbidity. The most common comorbidity was nephropathy (40.1%), followed by hypertension (25.4%), cardiac problems (21.1%), retinopathy (18.5%), and neuropathy (9.8%). Logistic regression model demonstrated that males had higher odds of hypertension (AOR = 1.734; 95% CI: 1.077–2.791), while poor diet adherence increased the risk of hypertension (AOR = 2.04; 95% CI: 1.195–3.481). Cardiac comorbidities were associated with lower education (primary: AOR = 3.743; 95% CI: 1.696–8.258; secondary: 2.986; 95% CI: 1.455–6.129) and were less common among individuals engaged in business professions (AOR = 0.351; 95% CI: 0.139–0.887). Nephropathy was strongly associated with uncontrolled glycemia (AOR = 2.220; 95% CI: 1.378–3.577) and with comparatively younger age (35–50 years) (AOR = 14.292; 95% CI: 6.36–32.19). Retinopathy risk decreased with dietary compliance (AOR = 0.525; 95% CI: 0.297–0.828), and food avoidance (AOR = 0.607; 95% CI: 0.385– 0.957).
conclusionThis study highlights a substantial burden of both microvascular and macrovascular comorbidities among patients with T2DM, with nephropathy being the most prevalent. Prioritize integrated care for diabetes and its related comorbidities with targeted support for age-specific patients, those with poor glycemic control, lower educational levels, longer disease duration, and poor dietary adherence.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.